Publication at Third Faculty of Medicine |
2023
Abstract
Entrectinib and its toxicity in a ROS1-positive non-small cell lung cancer patient was actually our first experience with this targeted therapy and also our experience with potential side effects. Although entrectinib has excellent data on treatment response and survival, it's important to consider side effects and monitor patients closely.
Sometimes the cost of treatment can be quite high.